Stayble Therapeutics AB

Equities

STABL

SE0013513652

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:18:17 2024-05-31 EDT			5-day change	1st Jan Change
0.253 ^SEK	-2.13%		+1.20%	-16.50%

05-21	Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-20	Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Stayble Therapeutics AB Publ Reports Earnings Results for the Full Year Ended December 31, 2020

May 03, 2021 at 05:00 am

Stayble Therapeutics AB publ announced earnings results for the full year ended December 31, 2020. For the full year, the company announced total revenue was SEK 77,826 compared to SEK 537,886 a year ago. Operating loss was SEK 14.925 million compared to SEK 6.874 million a year ago. Net loss was SEK 15.487 million compared to SEK 7.408 million a year ago.

Latest news about Stayble Therapeutics AB

Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-21	CI
Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-20	CI
Stayble Therapeutics Announces New Analyses of Phase IIb Study Strengthen Disc Herniation Project	12-18	CI
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Toleranzia Appoints Successor to Outgoing CFO	23-10-16	MT
Stayble Therapeutics Terminates Liquidity Provider Agreement	23-09-06	MT
Stayble Enters the First Patient in Herniated Disc Study	23-09-04	CI
Stayable Therapeutics Enrols First Patient for Herniated Discs Trial	23-08-28	MT
Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Certain Shares of Stayble Therapeutics AB are subject to a Lock-Up Agreement Ending on 22-AUG-2023.	23-08-21	CI
Stayble Therapeutics Phase IIb Study Nears the Final Line	23-07-24	CI
Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Sweden's Stayble Therapeutics Appoints Chief Medical Officer	23-04-19	MT
Stayble Therapeutics AB Adds Disc Herniation to the Pipeline - Study Approved	23-03-07	CI
Stayble Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-21	CI
Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-21	CI
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-15	CI
Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-17	CI
Stayble Therapeutics to Continue Clinical Trial of Degenerative Disc Disease Drug in Russia; Shares Up 7%	22-03-14	MT
Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-22	CI
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-18	CI
Stayble Therapeutics Presents Interim Results from the Phase IIb Study with STA363 Demonstrating Good Safety and Tolerability	21-11-10	CI
Stayble Therapeutics AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
Stayble Therapeutics AB Elects Ulf Björklund as Chairman	21-06-03	CI

Chart Stayble Therapeutics AB

Duration

Period

More charts

Company Profile

Stayble Therapeutics AB is a Sweden-based life science company developing an injectable treatment STA363 against chronic low back pain triggered by disc degeneration. The solutions are offered to the patients whose back pain persists after physiotherapy and drugs. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. Main focus of the Company is to develop STA363 as a new way of treatment for patients suffering from chronic disc-related low back pain. STA363 focuses on the two primary causes of pain in degenerative disc disease: leakage of inflammatory substances and disc instability. The mechanism of action of the treatment is to stabilize the disk segment and eliminate the possibility of disk leakage.

Sector

Biotechnology & Medical Research

Calendar

2024-08-19 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
STAYBLE THERAPEUTICS AB	-16.50%	762K
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs